Overview

Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Patients With Hepatic Impairment in Comparison to Healthy Volunteers

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

To investigate the pharmacokinetics of a single dose of BIIL 284 BS in patients with hepatic impairment in comparison to healthy subjects

Phase:

Phase 1

Details

Lead Sponsor:

Boehringer Ingelheim